Advertisement Pharmaceutical Business review - Page 5034 of 5290 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
September 16, 2026

Eli Lilly and QurCan sign genetic medicine deal

Eli Lilly and Company and QurCan Therapeutics have signed an exclusive research and collaboration agreement to develop genetic medicine therapeutics for diseases of the central and peripheral nervous systems.

Continue
QurCan uses its TERP platform to facilitate non-viral delivery of genetic medicines. Credit: MrWinn / Shutterstock.com.
September 16, 2026

Gilead and PAHO agree to expedite lenacapavir access for HIV prevention

Lenacapavir is currently approved in multiple countries for both HIV prevention and treatment of multi-drug-resistant HIV. Credit: Tatyana Frolova / Shutterstock.com.
September 15, 2026

Cheplapharm to take over 20 medicines and three sites from Sanofi

Cheplapharm will acquire production sites in Hungary, Singapore and France. Credit: Gorodenkoff / Shutterstock.com.

Contracts

January 23, 2025

Kamada to supply immune globulin products in Latin America

KAMRAB must be administered alongside a complete rabies vaccine regimen. Credit: Nappy on Unsplash.

Bavarian Nordic secures $156.8m US vaccine deal

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Deals

Deals January 20, 2025

Fermion and Simcere to partner on development of pain treatment drug

Pharmaceutical Business Review

WuXi Biologics and Sino Biopharm collaborate on monoclonal antibody discovery

Merck enhances ophthalmology portfolio with EyeBio acquisition

Biocon signs licensing and supply deal for diabetes drug in Brazil

Popular

  1. FDA reduces monitoring time for Amgen’s Imdelltra infusions
  2. Exegenesis Bio and Modalis sign research deal for Duchenne therapy
  3. ABEC to expand global manufacturing network with new Wilson facility
  4. Solstice Oncology secures $225m to drive porustobart’s development for cancer
  5. TwoStep Therapeutics secures $62.5m funding to advance TS-104

PRESS RELEASES

Gerresheimer Reports Slight Revenue Growth in Q1 2026 and a Strong Focus on Free Cash Flow
Gerresheimer Reports Slight Revenue Growth in Q1 2026 and a Strong Focus on Free Cash Flow
Uwe Röhrhoff Steps Down as Interim CEO of Gerresheimer AG
Uwe Röhrhoff Steps Down as Interim CEO of Gerresheimer AG
SCHOTT Pharma Expands Portfolio for Sensitive Biologics with cartriQ® BioPure
SCHOTT Pharma Expands Portfolio for Sensitive Biologics with cartriQ® BioPure
Pharmaceutical Business Review
SCHOTT Pharma and Nemera Deliver Verified Pen Injector Platform with Sterile Cartridge System
SCHOTT Pharma Invests in Sterile Cartridge Production in Hungary
SCHOTT Pharma Invests in Sterile Cartridge Production in Hungary

Suppliers

Whitepapers

Smoothly Through the Production Process: EVERIC™ Strong/Smooth Test
Smoothly Through the Production Process: EVERIC™ Strong/Smooth Test
Strengths and Weaknesses of Different Prefilled Syringes for Injections in Hospitals: A Case Study by Niklas Niederwieser and Patrick Gallagher SCHOTT AG
Strengths and Weaknesses of Different Prefilled Syringes for Injections in Hospitals: A Case Study by Niklas Niederwieser and Patrick Gallagher SCHOTT AG
Tracking the Cracking: How to Optimise Pharma Fill-and-Finish Processes by Use of Strength Testing and Fractography
Tracking the Cracking: How to Optimise Pharma Fill-and-Finish Processes by Use of Strength Testing and Fractography